Tokyo Medical and Dental University (TMDU) will introduce the Eyerising Myopia Management Device for its myopia patients as part of their treatment options.
The Eyerising Myopia Management Device uses patented repeated low-level red-light (RLRL) technology, which its Australian-based manufacturer says offers an efficacious, safe, non-invasive, and user-friendly solution for managing myopia in patients.
Eyerising International said use of its treatment at TMDU marked a significant milestone in the advancement of myopia management and treatment solutions.
“Both TMDU and Eyerising International are committed to ongoing research and development to further enhance the device’s capabilities and efficacy,” Eyerising stated.
The Australian Therapeutic Goods Administration registered Eyerising’s RLRL therapy in July 2023 (ARTG 412752), with the device now available in more than 30 other countries.
For more information about the Eyerising Myopia Management Device and the partnership between TMDU and Eyerising International, visit www.eyerisinginternational.com.
More reading
Eyerising Myopia Management Device granted TGA approval for home-use red-light therapy
Eyerising International refutes ‘inaccurate claims’ in University of Houston red light myopia study
Managing your practice’s myopia integration
